Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.
MiNK Therapeutics reported its financial results for Q4 and full year 2022, highlighting key advancements in their iNKT cell therapy programs. The company ended 2022 with a cash balance of $19.6 million, down from $38.9 million in 2021. Net loss for Q4 2022 was $7.8 million, or $0.23 per share, showing an increase from $5.8 million in Q4 2021. MiNK's therapy, AgenT-797, demonstrated clinical activity in solid tumors and will feature at the upcoming AACR Annual Meeting. The firm is advancing plans for combination studies and manufacturing capabilities to enhance production efficiency.
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced an upcoming presentation of updated clinical data on its allo-iNKT cell therapy, agenT-797, scheduled for the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. The presentation, titled 'Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs),' will be conducted by Dr. Benedito Carneiro on April 18, 2023. MiNK is focused on developing innovative iNKT cell therapies for cancer treatment, leveraging a scalable manufacturing platform. This update could impact investor sentiment based on the therapy's progress in advanced solid tumors.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced the release of its fourth quarter and full year 2022 financial results on March 21, 2023, before market open. The leadership team will conduct a conference call and webcast at 8:30 a.m. ET the same day to discuss these results and provide a corporate update. MiNK is focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, utilizing a scalable manufacturing platform. For more details, investors can join the live webcast or access it later through the company’s website.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28 at 9:00 AM ET. The chat will focus on MiNK's pioneering work in allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested participants can access the live chat here, with a replay available on MiNK's website thereafter.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. The live chat can be accessed via B. Riley's website, with a replay available afterward on MiNK's Events and Presentations page. The conference, taking place on January 18-19, will showcase over 30 healthcare companies focusing on innovations in cancer treatment, featuring discussions by key opinion leaders in the field.
MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET. The event will be accessible live via a provided link, with a replay available on the MiNK website afterward. Recently, MiNK presented new data from five presentations at the Society for Immunotherapy of Cancer Annual Meeting on November 10th, showcasing their innovative iNKT cell therapies aimed at treating cancer and immune-mediated diseases.
MiNK Therapeutics announced promising results for its allogeneic iNKT cell therapy, agenT-797, showcasing early clinical activity in solid tumors with 27% of patients achieving disease stabilization alone and 66% in combination with pembrolizumab or nivolumab. Noteworthy is the survival benefit observed in viral ARDS patients, with a 70% survival rate versus 10% in controls. Moreover, agenT-797 demonstrated a favorable safety profile with no cytokine release syndrome reported, and the company is advancing new candidates for next-generation CAR-iNKT therapies.
MiNK Therapeutics reported third-quarter 2022 financial results, highlighting a net loss of $6.3 million ($0.19 per share), a significant reduction from a net loss of $14.3 million ($0.59 per share) in Q3 2021. The company had a cash balance of $24.2 million as of September 30, 2022, down from $38.9 million at the end of 2021. Operational cash usage increased, reflecting the internalization of cGMP manufacturing for clinical trials. The firm will present at the Society of Cancer Immunotherapy Meeting, showcasing clinical data on its iNKT cell therapies.
MiNK Therapeutics will release its third quarter 2022 financial results on November 3rd, 2022, before the market opens. A conference call is scheduled for 8:30 a.m. ET the same day, providing insights into the company's progress in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
The company focuses on scalable and reproducible manufacturing methods for its therapies, aiming for off-the-shelf delivery to patients.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
